Jasper Therapeutics: A Promising Player in Mast Cell-Driven Disease Therapies

REDWOOD CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- jasper therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, is presenting updated clinical data from the Phase 1b/2a BEACON study, as well as data from four preclinical studies evaluating briquilimab, at the AAAAI 2025 Annual Meeting, being held February 28 - March 3, 2025, in San Diego, CA.

The BEACON update, based on a data-cut date of January 31, 2025, features approximately one month of additional dosing and follow-up from the 49 participants covered in Jasper’s preliminary data disclosure on January 8, 2025. Briquilimab continues to be well tolerated in the study and has continued to demonstrate a favorable safety profile, with no additional adverse events (AEs) potentially related to c-Kit blockade observed. The data collected in the study to-date support advancing briquilimab into a registrational program in CSU, beginning with a planned Phase 2b operationally adaptive study expected to commence in the second half of 2025. Final dose selection for the Phase 2b study will be further informed by additional clinical data from patients treated at doses of 180mg and higher, expected to be reported mid-year 2025.

“I am pleased to present updated data from the BEACON study at AAAAI, which continue to demonstrate that treatment with briquilimab leads to rapid and deep clinical responses in omalizumab-experienced patients with moderate to severe CSU,” said Thomas B. Casale, M.D., Professor of Medicine and Pediatrics, University of South Florida Morsani College of Medicine. “The safety profile observed is also highly encouraging, with a low frequency of c-Kit related adverse events, which were transient, low-grade, and did not result in any dose delays or discontinuations. The favorable safety data reported in the study are supported by the predictable drug clearance observed, which may allow for restoration of signaling on c-Kit-expressing cells between doses. In addition, the early Tmax observed was consistent with rapid onset of clinical response. Taken together, I believe this data set underscores the potential of briquilimab to serve as a differentiated treatment option for patients with CSU.”

“We remain very excited by the efficacy and safety data generated in the BEACON study,” said Ronald Martell, President and Chief Executive Officer of jasper. “We believe that these data demonstrate the potential of briquilimab to differentiate from other therapies, approved and in-development, with regard to onset of action, depth of response, and safety/tolerability. With a substantial number of additional patients being enrolled in the BEACON and SPOTLIGHT studies, as well as patients rolling over from those studies to the Open-Label Extension study, we look forward to reporting data from approximately 70 additional patients treated with briquilimab doses of 180mg or higher around mid-year 2025. These data will inform final dose selection for our planned Phase 2b operationally adaptive study expected to commence later this year.”

Details of the presentations are as follows:
Abstract Title: Initial Results from BEACON, a Phase 1b/2a Dose Escalation Study of the anti-c-Kit Briquilimab Antibody in Adults with Chronic Spontaneous Urticaria (CSU)
Publication Number: L24
Session Title: Late Breaking Oral Abstract Session
Session Type: Oral Abstract Session
Presentation Date / Time: Saturday, March 1, 2025; 2:55 p.m. PST
Abstract Title: Initial Results from BEACON, a Phase 1b/2a Dose Escalation Study of the anti-c-Kit Briquilimab Antibody in Adults with Chronic Spontaneous Urticaria (CSU)
Poster Number: L24
Session Title: Late Breaking Poster Session I
Session Type: Poster Session
Session Date / Time: Saturday, March 1, 2025; 9:45 - 10:45 a.m. PST
Abstract Title: Briquilimab, an Anti-c-Kit Antibody, Induces Durable Depletion of Mast Cells (MCs) Across Multiple Tissues in Mice Expressing Chimeric Human/Mouse CD117 (c-Kit)
Poster Number: 540
Session Title: Novel Mechanisms of Mast Cells, Basophils and IgE
Session Type: Poster Session
Session Date / Time: Saturday, March 1, 2025; 9:45 - 10:45 a.m. PST
Abstract Title: Briquilimab Potently Inhibits Stem Cell Factor (SCF)/c-Kit Signaling and Induces Mast Cell Apoptosis
Poster Number: 541
Session Title: Novel Mechanisms of Mast Cells, Basophils and IgE
Session Type: Poster Session
Session Date / Time: Saturday, March 1, 2025; 9:45 - 10:45 a.m. PST
Abstract Title: Briquilimab, an Anti-Human CD117 Antibody, Prevents Epicutaneous Oxazolone-Induced Features of Dermatitis in Mouse Model Expressing Chimeric Human/Mouse CD117
Poster Number: 662
Session Title: Atopic Dermatitis, Contact Dermatitis, Urticaria, Angioedema
Session Type: Poster Session
Session Date / Time: Sunday, March 2, 2025; 9:45 - 10:45 a.m. PST
Abstract Title: Briquilimab, an Anti-Human CD17 Antibody, Treats Low-Calcemic Vitamin D3 Analog MC903-Induced Dermatitis in Mouse Model Expressing Chimeric Human/Mouse CD117
Poster Number: 690
Session Title: Atopic Dermatitis, Contact Dermatitis, Urticaria, Angioedema
Session Type: Poster Session
Session Date / Time: Sunday, March 2, 2025; 9:45 - 10:45 a.m. PST

Jasper Therapeutics' briquilimab has shown promising results in clinical and preclinical studies, demonstrating its potential as a targeted therapy for mast cell-driven diseases. The updated data from the BEACON study, along with the preclinical findings, support the advancement of briquilimab into a registrational program for CSU. The favorable safety profile, rapid onset of action, and depth of response observed in the study differentiate briquilimab from other therapies, approved and in-development, for the treatment of CSU. As Jasper continues to enroll additional patients and generate more data, investors should keep an eye on this promising biotechnology company.